Veracyte (VCYT) Insider Karin Eastham Sells $197K of Stock

Karin Eastham, an insider at Veracyte, Inc., sold 3,729 shares of the company in a planned transaction on June 18, 2026. The shares were sold at an average price of $52.89, totaling about $197,223.83.

Insider Buying and Selling at Veracyte, Inc.

The recent insider activity at Veracyte, Inc. saw Karin Eastham selling 3,729 shares on June 18, 2026, as part of a planned transaction. Other insiders, including Eliav Barr, Muna Bhanji, Robert Epstein, Evan Jones, and David Brent Shafer, each purchased 5,272 shares on June 11, 2026, though these transactions were not planned.

Other Institutional Activity in Veracyte, Inc.

Among Veracyte's institutional investors, BlackRock, Inc. increased its holdings by 43,817 shares, ending with 13,172,618 shares valued at about $424.29 million. FMR LLC significantly boosted its position by 2,025,640 shares, now holding 7,763,849 shares worth approximately $250.07 million. Artisan Partners Limited Partnership reduced its stake by 766,671 shares, bringing its total to 5,496,370 shares valued at $177.04 million. State Street Corp added 682,677 shares, reaching a total of 5,043,590 shares worth $162.45 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, holding 4,444,730 and 3,532,232 shares, respectively.

Veracyte, Inc. Stock Up 33.7%

Shares of NasdaqGM:VCYT traded near $53.19 on Tuesday. Veracyte, Inc. has a market cap of approximately $4.28 billion and a P/E ratio of 49.7, reflecting its profitability. The stock's 52-week range is between $22.61 and $53.81, with a 50-day moving average of $40.73 and a 200-day moving average of $38.43. Veracyte maintains a strong balance sheet with a current ratio of 9.31 and a quick ratio of 8.72.

Analysts Set New Price Targets

On June 1, 2026, Needham maintained its buy rating for Veracyte, Inc. with a price target of $57. Canaccord Genuity, on May 6, 2026, maintained a hold rating with a $42 price target, while UBS also maintained a buy rating with a $52 target. The overall analyst consensus is a buy, with a mean price target of $49.10 based on 10 analyst opinions.

About Veracyte, Inc.

Veracyte, Inc., based in South San Francisco, California, operates in the healthcare sector, focusing on diagnostics and research. The company offers genomic tests for various cancers, including thyroid, prostate, bladder, breast, and lung. It also provides the nCounter analysis system. With around 755 employees, Veracyte is led by CEO Marc A. Stapley.

Bottom Line

Karin Eastham's planned sale of shares is a notable insider transaction at Veracyte, Inc., reflecting ongoing activity within the company. Veracyte, with its strong position in the diagnostics field, continues to attract interest from institutional investors. Analyst opinions show a mix of buy and hold ratings, with a positive consensus outlook. Investors should note that insider transactions are reported after they occur, providing a historical view rather than a current snapshot.